by Peter Hotez, M.D., Ph.D. Hotez is Dean of the National School of Tropical Medicine at Baylor College of Medicine where he is also the Texas Children’s Hospital Endowed Chair in Tropical Pediatrics and the University Professor of Biology at Baylor University.

Smallpox was one of the most terrifying diseases in human history. Smallpox plagued humanity for thousands of years, killing one-third of its victims and disfiguring those who survived.

Dengue Vaccine Initiative Statement on Results of Studies on the Efficacy and Long-Term Safety of Sanofi Pasteur’s Dengue Vaccine Candidate in Dengue-Endemic Regions

WASHINGTON DC – JULY 27, 2015—A study titled “Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease” (Hadinegoro et al.), published today in The New England Journal of Medicine, assesses vaccine efficacy and interim long-term safety results of Sanofi Pasteur’s dengue vaccine candidate, CYD-TDV, across three clinical trials in dengue-endemic countries within Asia-Pacific and Latin America. This analysis marks a significant scientific milestone in Sanofi Pasteur’s efforts to develop a dengue vaccine.
This blog post was originally published on Impatient Optimists, by Pascal Barollier, Director of Communications at Gavi, the Vaccine Alliance.


Subscribe to RSS - Vaccine Advocacy and Education